# Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors

> **NCT00095160** · PHASE1 · COMPLETED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 42 (—)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** 852A

## Key facts

- **NCT ID:** NCT00095160
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 42 (—)
- **Last updated:** 2017-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095160, "Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00095160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*